We are live on ! Find out more
ATNM icon

Actinium Pharmaceuticals
ATNM

54 hedge funds and large institutions have $5.27M invested in Actinium Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.35% less ownership

Funds ownership: 17.34% → 16.99% (-0.35%)

10% less funds holding

Funds holding: 60 → 54 (-6)

14% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 14

28% less capital invested

Capital invested by funds: $7.36M → $5.27M (-$2.08M)

42% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 12

Holders
54
Holders Change
-6
Holders Change %
-10%
% of All Funds
0.66%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
12
Reduced
14
Closed
12
Calls
$147K
Puts
–
Net Calls
+$147K
Net Calls Change
-$72K

Top Buyers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
+$152K
2
Renaissance Technologies
Renaissance Technologies
New York
+$96.1K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$49.4K
4
Northern Trust
Northern Trust
Illinois
+$39.5K
5
TSS
Two Sigma Securities
New York
+$27.3K

Top Sellers

Rank Fund Capital Flow
1
Squarepoint
Squarepoint
New York
-$89.4K
2
B
Bailard
California
-$78.7K
3
Jane Street
Jane Street
New York
-$70K
4
Millennium Management
Millennium Management
New York
-$44K
5
Cetera Investment Advisers
Cetera Investment Advisers
Illinois
-$20.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
Osaic Holdings
26
Osaic Holdings
Arizona
$19.9K -$476 -400 -2%
Wells Fargo
27
Wells Fargo
California
$19.7K – – –
Qube Research & Technologies (QRT)
28
Qube Research & Technologies (QRT)
United Kingdom
$18K -$909 -764 -4%
UBS Group
29
UBS Group
Switzerland
$14.5K +$17.3K +14,522 +15,127%
Morgan Stanley
30
Morgan Stanley
New York
$13.5K -$6.51K -5,473 -29%
VF
31
Virtu Financial
New York
$12K +$14.7K +12,324 New
CFO
32
Callan Family Office
Pennsylvania
$11.9K -$13.9K -11,659 -49%
IFPG
33
Intrepid Financial Planning Group
Indiana
$10.5K – – –
LFAS
34
Level Four Advisory Services
Texas
$9.95K – – –
SAI
35
Savvy Advisors Inc
New York
$9.95K – – –
VGA
36
Vanguard Global Advisers
Pennsylvania
$8.85K +$10.6K +8,893 New
Rockefeller Capital Management
37
Rockefeller Capital Management
New York
$3.98K – – –
SPIA
38
Steward Partners Investment Advisory
New York
$2.16K – – –
JP Morgan Chase
39
JP Morgan Chase
New York
$1.48K – – –
ASN
40
Advisory Services Network
Georgia
$1.45K +$1.74K +1,460 New
Federated Hermes
41
Federated Hermes
Pennsylvania
$1.4K – – –
National Bank of Canada
42
National Bank of Canada
Quebec, Canada
$1K +$197 +166 +19%
Citigroup
43
Citigroup
New York
$675 +$294 +247 +57%
SS
44
SBI Securities
Japan
$539 – – –
Jones Financial Companies
45
Jones Financial Companies
Missouri
$362 – – –
Carson Wealth (CWM LLC)
46
Carson Wealth (CWM LLC)
Nebraska
$349 -$320 -269 -43%
PAI
47
Pittenger & Anderson Inc
Nebraska
$340 – – –
Nisa Investment Advisors
48
Nisa Investment Advisors
Missouri
$328 -$747 -628 -66%
IRC
49
Investors Research Corp
Georgia
$299 – – –
BNP Paribas Financial Markets
50
BNP Paribas Financial Markets
France
$236 – – –
1
2
3

ATNM Hedge Fund Activity: Q1 2026 in Review

54 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q1 2026, worth a combined $5.27M — down 28% from $7.36M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of ATNM and 7 opened new positions — a net loss of 5 holders — while 14 trimmed existing stakes and 12 added.

The largest buyer was Two Sigma Investments, adding an estimated $152K. The largest seller was Squarepoint, exiting entirely with an estimated $89.4K sold.

  • 54 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q1 2026, down from 60 in Q4 2025.
  • Funds reported $5.27M of Actinium Pharmaceuticals stock for Q1 2026, down 28% quarter-over-quarter.
  • 7 funds opened new Actinium Pharmaceuticals positions in Q1 2026 and 12 closed out, a net change of -5 holders.
  • The largest Actinium Pharmaceuticals buyer in Q1 2026 was Two Sigma Investments, an estimated $152K added.
  • The largest Actinium Pharmaceuticals seller in Q1 2026 was Squarepoint, an estimated $89.4K sold.

Based on aggregated 13F filings for Q1 2026.